Patients featured are on CABENUVA. Individuals featured have been compensated by ViiV Healthcare.

Make the switch to CABENUVA. Data from SOLAR, the first head-to-head switch study comparing every-2-month CABENUVA to continuing daily oral BIKTARVY1:

BEYOND: Explore the ongoing, real-world evidence study2

Explore BEYOND

Calendar icon Calendar icon

You can offer people with HIV two months between doses.

CABENUVA is the only complete, long-acting regimen for the treatment of HIV.

Identify patients for CABENUVA in your practice

"Some days taking daily oral therapy is fine, but some days it's a challenge."

Jorge—Patient Ambassador

See Jorge’s HIV treatment story

CABENUVA access and acquisition

Get comprehensive support from benefit verification to reimbursement to acquisition to co-pay collection.

Start now

Questions to ask your patients about taking daily oral therapy for HIV

Question mark icon Question mark icon

“How would you feel if you didn't have to take a daily oral therapy?”

“Would a long-acting regimen be a better fit for you?”


  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577.
  2. Sinclair G, et al. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at: IDWeek on HIV Treatment; October 15-11, 2023; Boston, MA.